FDA & Government News

May 21, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Conexiant

May 20, 2026

FDA Approves Expanded Liquid Biopsy Panel

Updated liquid biopsy combines genomic and epigenomic profiling for companion diagnostic use across multiple tumor types.

Conexiant

May 20, 2026

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Conexiant

May 19, 2026

Rare Ebola Strain Sparks Global Alert

CDC urges travelers returning from Central Africa to monitor for Ebola symptoms for 21 days.

Conexiant

May 18, 2026

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

May 18, 2026

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Conexiant

May 15, 2026

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

Kff Health News

May 13, 2026

RFK Jr. Takes Health Agenda on the Road

Touring Ohio, RFK Jr. highlights food quality and recovery services while steering attention away from vaccine controversies.

Kff Health News

May 12, 2026

Makary Resigns as FDA Commissioner Following Policy Disputes

Transition follows disputes over vaccine policy, food additive regulation, and flavored vaping product authorization

Conexiant

May 12, 2026

FDA Clears AI Sepsis Warning System

An FDA-cleared AI tool developed at Johns Hopkins detects sepsis up to 48 hours earlier than clinicians — and has cut related deaths by 18%.

Conexiant

Grip Strength Plus Waist Size May Flag Risk T2D Risk

FDA & Government News

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

FDA Approves Expanded Liquid Biopsy Panel

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Rare Ebola Strain Sparks Global Alert

FDA Clears Golimumab Biosimilars

Daily News

FDA Approves Baxdrostat for Resistant Hypertension

Why FDA Said No to a Melanoma Drug

RFK Jr. Takes Health Agenda on the Road

Makary Resigns as FDA Commissioner Following Policy Disputes

FDA Clears AI Sepsis Warning System

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

Grip Strength Plus Waist Size May Flag Risk T2D Risk

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

The New Optometrist

The Pathologist

FDA & Government News

Daily News

Recommendations